Novartis
NVS
1,515 hedge funds and large institutions have $18.4B invested in Novartis in 2025 Q4 according to their latest regulatory filings, with 209 funds opening new positions, 496 increasing their positions, 478 reducing their positions, and 67 closing their positions.
212% more first-time investments, than exits
New positions opened: 209 | Existing positions closed: 67
45% more funds holding in top 10
Funds holding in top 10: 11 → 16 (+5)
8% more funds holding
Funds holding: 1,405 → 1,515 (+110)
7% more capital invested
Capital invested by funds: $17.2B → $18.4B (+$1.19B)
4% more repeat investments, than reductions
Existing positions increased: 496 | Existing positions reduced: 478
0.02% more ownership
Funds ownership: 6.92% → 6.95% (+0.02%)
38% less call options, than puts
Call options by funds: $382M | Put options by funds: $620M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$150M |
| 2 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$117M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$103M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$79.8M |
| 5 |
VanEck Associates
New York
|
+$67.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$231M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$206M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$182M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$112M |
| 5 |
Renaissance Technologies
New York
|
-$70M |
NVS Hedge Fund Activity: Q4 2025 in Review
1,515 of the 8,284 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2025, worth a combined $18.4B — up 6.9% from $17.2B a quarter earlier.
Buyers outnumbered sellers: 209 funds opened new NVS positions and 67 closed out — a net gain of 142 holders — while 496 added to existing stakes and 478 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $150M. The largest seller was Primecap Management, cutting an estimated $231M.
- 1,515 institutional investors held Novartis (NVS) as of Q4 2025, up from 1,405 in Q3 2025.
- Funds reported $18.4B of Novartis stock for Q4 2025, up 6.9% quarter-over-quarter.
- 209 funds opened new Novartis positions in Q4 2025 and 67 closed out, a net change of +142 holders.
- The largest Novartis buyer in Q4 2025 was Morgan Stanley, an estimated $150M added.
- The largest Novartis seller in Q4 2025 was Primecap Management, an estimated $231M sold.
Based on aggregated 13F filings for Q4 2025.